AstraZeneca and Amgen co-develop and co-commercialize Tezspire under an April 2012 agreement. The partners are now planning ...

Limited opportunities and burnout are just two reasons biopharma professionals stop looking for work, with some pivoting away ...

Biopharmas developing CAR T therapies for autoimmune indications face major barriers to maximizing the market. Advances in ...

Current leaders Eli Lilly and Novo Nordisk have cornered the early market for weight loss therapeutics, but several other ...

Vitruvias Therapeutics has “ceased operations” after voluntarily recalling a batch recall of generic thyroid tablets due to ...

In this episode of Denatured, you’ll hear from Hilary Rosselot, executive director at the National Fragile X Foundation and ...

Two recruiting experts discuss the main areas where biopharma employers and candidates don’t match up, from how the hiring ...

Setbacks to efforts to use Cellares’ automated platform to make an approved CAR-T cell therapy led BMS to terminate its ...

The FDA granted the approval of Revolution Medicines' daraxonrasib, now to be known as Rasonque, in pancreatic adenocarcinoma ...

Gastroesophageal adenocarcinoma presents the biggest market opportunity for Jazz Pharmaceuticals’ Ziihera, according to ...

The Phase 3 readout is the first for ivonescimab beyond non-small cell lung cancer to show a significant overall survival ...

Though the potential change is unconfirmed, media outlets reported Wednesday that one deputy commissioner would focus on the ...